Utility of Non-Invasive, Machine Learning-Based Proteomic Profiling as a Biomarker to Predict Drug Efficacy

This event ran on Wednesday October 14 | 9am PST, 12pm EST, 5pm BST

Engage Webinar hosted by...

Biodesix

Over the past 10 years, biomarkers have made a significant impact on the oncology therapeutic landscape, but there is still room for improvement to appropriately identify the right patient for the right treatment. Research trends have begun to shift to look at proteomics for a more comprehensive view of the patient’s dynamic disease state and an understanding of their immune profile and immune response to cancer.

Join Biodesix for a webinar demonstrating how artificial intelligence is being coupled with mass spectrometry to extract important protein-based biological information from blood samples for biomarker discovery and diagnostic test development. 

Webinar Leaders

Mark McCleland, Ph.D.

Principal Scientific Manager, Oncology Biomarker Development - Genentech

Robert Georgantas III, Ph.D.

Senior Vice President, Research and Translational Science - Biodesix, Inc.

This talk will be followed by a research case study from Genentech on the utilization of a mass spectrometry-based
proteomic classifier designed to identify non-small cell lung cancer patients that benefit most from atezolizumab
treatment in the POPLAR clinical trial.

Over the course of 45 minutes you will have expert insight from Robert Georgantas, SVP of Research & Translational Science at Biodesix and Mark McCleland, Principal Scientific Manager, Oncology Biomarker Development at Genentech.
The webinar is designed to equip you with expert insight necessary for successfully understanding the benefits of proteomic profiling for novel insights in your therapeutic development programs. You will have the opportunity to pose questions on these topics using our interactive webinar platform, so whether you are questioning what technologies to invest in for early biomarker development, looking to fine tune your drug-diagnostic clinical strategy or simply interested in the application
of biomarkers and diagnostics, then this is the webinar for you.

Register today for your opportunity to remain up to date on latest advice and lessons learned to prime yourself for proteomic biomarker research excellence.

We hope to see you there!

Engage Webinar hosted by...

Biodesix

Who are Biodesix?

Biodesix is a leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease. Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies and leverage our proprietary artificial intelligence platform to discover innovative diagnostic tests for clinical use. Our technology agnostic approach allows for a broader and more holistic understanding of each patient’s disease state. Additionally, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. See more information at www.biodesix.com.

This Webinar Will Provide You With:

  • An overview of research trends which have begun to shift to proteomics to allow for a more comprehensive view of the patient’s dynamic disease state and an understanding of their immune profile
  • Expert insights into employing artificial intelligence combined with mass spectrometry technology can extract important protein-based biological information from blood samples for biomarker discovery and diagnostic test development
  • A unique virtual meeting which allows you to access the latest perspectives on how novel technologies and non-invasive biomarkers are being explored for clinical trial applications with checkpoint inhibitors
  • A key opportunity to listen and pose questions in regards to a case study on how biomarker discovery and validation research, using mass spectrometry-based proteomic classifier, helped to identify non-small cell lung cancer patients that benefit most from Atezolizumab treatment in the POPLAR clinical trial
  • Your unique chance to ask all your burning questions to experts in mass spectrometry for proteomic biomarker discovery and validation for clinical therapeutic applications in oncology